In vivo 31P NMR spectroscopy shows an increase in glycerophosphorylcholine concentration without alterations in mitochondrial function in the prefrontal cortex of medicated schizophrenic patients at rest

European Journal of Neuroscience

Volumn 20, Issue 3, 2004, Pages 749-756

  Shirayama, Yukihiko ^a,b,d   Yano, Toshio ^a,b   Takahashi, Kiyohisa ^a   Takahashi, Seizo ^b,c   Ogino, Takashi ^b  

^a National Center of Neurology and Psychiatry   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c JAPAN WOMEN'S UNIVERSITY   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

Author keywords

Magnetic resonance spectroscopy; Phosphorus metabolism; Schizophrenia

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CREATINE PHOSPHATE; GLYCEROPHOSPHOETHANOLAMINE; GLYCEROPHOSPHORYLCHOLINE; PHOSPHATE; PHOSPHOETHANOLAMINE; PHOSPHORYLCHOLINE; NEUROLEPTIC AGENT; PHOSPHORUS;

ADULT; ARTICLE; BRAIN MITOCHONDRION; CLINICAL ARTICLE; CONTROLLED STUDY; HIGH ENERGY PHOSPHATE; HUMAN; HUMAN TISSUE; IMAGE QUALITY; IN VIVO STUDY; LIPID BRAIN LEVEL; MALE; METABOLITE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOLIPID METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PHOSPHORYLATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; SIDE EFFECT; TISSUE DISTRIBUTION; BRAIN LEVEL; CASE CONTROL STUDY; CELL MEMBRANE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; ENERGY METABOLISM; METABOLISM; METHODOLOGY; MITOCHONDRION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; CASE-CONTROL STUDIES; CELL MEMBRANE; ENERGY METABOLISM; GLYCERYLPHOSPHORYLCHOLINE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MITOCHONDRIA; PHOSPHATES; PHOSPHORUS ISOTOPES; PREFRONTAL CORTEX; SCHIZOPHRENIA;

EID: 3843072213     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2004.03524.x     Document Type: Article

References (65)

1. Andreasen, N.C. (1982) Negative symptoms in schizophrenia: definition and reliability. Arch. Gen. Psychiatry, 139, 784-788.
2. Ascher, P. & Nowak, L. (1987) Electrophysiological studies of NMDA receptors. Trends Neurosci., 10, 284-288.
3. Barany, M., Chang, Y.C., Arus, C., Rustan, T., Frey, W.H. 2nd. (1985) Increased gycerol-3-phosphorylcholine in post-mortem Alzheimer's brain. Lancet, 1, 517.
4. 31P MRS of the schizophrenic brain in vivo. J. Comput. Assist. Tomogr., 12, 272-275.
5. 31P magnetic resonance spectroscopy reveals osmotic and metabolic disturbances in human hepatic encephalopathy. J Neurochem., 71, 1564-1576.
6. Bottomley, P.A., Hardy, C.J., Cousins, J.P., Armstrong, M. & Wagle, W.A. (1990) AIDS dementia complex: brain high-energy phosphate metabolite deficits. Radiology, 176, 407-411.
7. 31P MRS in vivo. Part 1: cerebrum, cerebellum, cerebral gray and white matter. Magn. Reson. Med., 32, 447-452.
8. Callicot, J.H., Bertolino, A., Egan, M.F., Mattay, V.S., Langheim, F.J.P. & Weinberger, D.R. (2000) Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry, 157, 1646-1651.
9. 2O PET study during single-trial stroop task performance. Am. J. Psychiatry, 154, 1670-1675.
10. Cavelier, L., Jazin, E.E., Eriksson, I., Prince, J., Bave, U., Oreland, L. & Glyllesten, U. (1995) Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics, 29, 217-224.
11. Chance, B., Leigh, J.S. Jr, Kent, J., Mccully, K., Nioka, S., Clark, B.J., Maris, J.M. & Graham, T. (1986) Multiple controls of oxidative metabolism in living tissues as studied by phosphorus magnetic resonance. Proc. Natl Acad. Sci. USA, 83, 9458-9462.
12. 31P NMR. Neuroreport, 8, 287-291.
13. 31P magnetization transfer studies of creatine kinase kinetics in living rabbit brain. Magn. Reson. Med., 5, 1-12.
14. 31Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biol. Psychiatry, 36, 503-510.
15. Duncan, G.E., Sheitman, B.B. & Lieberman, J.A. (1999) An integrated view of pathophysiological models of schizophrenia. Brain Res. Rev., 29, 250-264.
16. 2 and its role in brain tissue. J. Neurochem., 69, 889-901.
17. Fazeli, M.S. (1992) Synaptic plasticity: on the trail of the retrograde messenger. Trends Neurosci., 15, 115-117.
18. Foster, P. (1989) Neuroleptic equivalence. Pharmac. J., 243, 431-432.
19. 31P magnetic resonance chemical shift imaging. Acta. Psychiat. Scand., 86, 455-462.
20. Fukuzako, H., Fukuzako, T., Kodama, S., Hashiguchi, T., Takigawa, M. & Fujimoto, T. (1999) Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients. Neuropsychopharmacology, 21, 542-549.
21. 2 activity in schizophrenia: a replication study. Biol. Psychiatry. 28, 495-501.
22. 2 activity in schizophrenia. Schizophrenia Res., 16, 1-6.
23. Goldberg, T.E., Weinberger, D.R., Berman, K.F., Pliskin, N.H. & Podd, M.H. (1987) Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin card sorting test. Arch. Gen. Psychiatry, 44, 1008-1014.
24. Gruetter, R., Fusch, C., Martin, E. & Boesch, C. (1993) Determination of saturation factors in 31P NMR spectra of the developing human brain. Magn. Reson. Med., 29, 7-11.
25. Hubesch, B., Ssppey-Marinier, D., Roth, K., Meyerhoff, D., Matson, G.B. & Weiner, M.W. (1990) P-31 MR spectroscopy of normal human brain and brain tumors. Radiology, 174, 401-409.
26. Ingvar, D.H. & Franzen, G. (1976) Distribution of cerebral activity in chronic schizophrenia. Lancet, 2, 1484-1486.
27. Jensen, J.E., Al-Semaan, Y.M., Williamson, P.C., Neufeld, R.W.J., Menon, R.S., Schaeffer, B., Densmore, M. & Drost, D.J. (2002) Regional-specific changes in phopholipid metabolism in chronic, medicated schizophrenia. Br. J. Psychiatry, 180, 39-44.
28. Jentsch, J.D., Taylor, J.R. & Roth, R.H. (2000) Phencyclidine models of frontal cortical dysfunction in nonhuman primates. Neuroscientists, 6, 263-270.
29. Kato, T., Shioiri, T., Murashita, J., Hamakawa, H., Inubushi, T. & Takahashi, S. (1995) Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Psychiatry Res. Neuroimaging, 61, 151-160.
30. Kegeles, S.K., Humaran, T.J. & Mann, J.J. (1998) In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol. Psychiatry, 44, 382-398.
31. Keshaven, M.S., Stanley, J.A. & Pettegrew, J.W. (2000) Magnetic resonance spectroscopy in schizophrenia: methodological issues and finding-part II. Biol. Psychiatry, 48, 369-380.
32. Lara, R.S., Matson, G.B., Hugg, J.W., Maudsley, A.A. & Weiner, M.W. (1993) Quantitation of in vivo phosphorus metabolites in human brain with magnetic resonance spectroscopic imaging (MRSI). Magn. Reson. Imaging, 11, 273-278.
33. Liddle, F.F., Friston, K.J., Frith, C.D., Hirsch, S.R., Jones, T. & Frackowiak, R.S.J. (1992) Patterns of cerebral blood flow in schizophrenia. Br. J. Psychiatry, 160, 179-186.
34. Lin, X.-H., Kitamura, N., Hashimoto, T., Shirakawa, O. & Maeda, K. (1999) Opposite changes in phophoinositide-specific phopholipase C immunoreactivity in the left prefrontal and superior temporal cortex of palients with chronic schizophrenia. Biol. Psychiatry, 46, 1665-1671.
35. Luyten, P.R., Groen, J.P., Vermeulen, J.W.A.H. & den Hollander, J.A. (1989) Experimental approaches to image localized human 31P NMR spectroscopy. Magn. Reson. Med., 11, 1-21.
36. Manoach, D.S., Gollub, R.L., Benson, E.S., Searl, M.M., Goff, D.C., Halpern, E., Saper, C.B. & Rauch, S.L. (2000) Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol. Psychiatry, 48, 99-109.
37. 31P NMR spectra of the human brain in vivo. NMR Biomed., 7, 237-242.
38. 31P-NMR. J. Appl. Physiol., 62, 2094-2102.
39. Nitsch, R.M., Blusztajn, J.K., Pittas, A.G., Slack, B.E., Growdon, J.H. & Wurtman, R.J. (1992) Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl Acad. Sci. USA, 89, 1671-1675.
40. 2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry, 34, 641-649.
41. Pangerl, A.M., Steudle, A., Jaroni, H.W., Rufer, R. & Gattaz, W.F. (1991) Increased platelet membrane lysophophatidylcholine in schizophrenia. Biol. Psychiatry, 30, 837-840.
42. 31P and H nuclear magnetic resonance studies. Neurology, 35, 1681-1688.
43. Pettegrew, J.W., Keshavan, M.S., Panchalingam, K., Strychor, S., Kaplan, D.B., Tretta, M.G. & Allen, M. (1991) Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. Arch. Gen. Psychiatry, 48, 563-568.
44. 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biol. Psychiatry, 45, 687-693.
45. 2. Arch. Gen. Psychiatry, 54, 487-494.
46. 2 activities in brain of patients with schizophrenia. Brain Res., 821, 407-413.
47. Roth, K., Hubesch, B., Meyerhoff, D.J., Naruse, S., Gober, J.R., Lawry, T.J., Boska, M.D., Matson, G.B. & Weiner, M.W. (1989) Noninvasive quantitation of phosphorus metabolites in human tissue by NMR spectroscopy. J. Magn. Reson., 81, 299-311.
48. Sabri, O., Erkwoh, R., Schreckenberger, M., Owega, A., Sass, H. & Buell, U. (1997) Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet, 349, 1735-1739.
49. Shioiri, T., Kato, T., Inubushi, T., Murashita, J. & Takahashi, S. (1994) Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Res. Neuroimaging, 55, 223-235.
50. Shioiri, T., Someya, T., Murashita, J., Kato, T., Hamakawa, H., Fujii, K. & Inubushi, T. (1997) Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia. Psychiatry Res. Neuroimaging, 76, 113-122.
51. Sigmundsson, T., Maier, M., Toone, B.K., Williams, S.C.R., Simmons, A., Greenwood, K. & Ron, M.A. (2003) Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophrenia Res., 64, 63-71.
52. Stanley, J.A., Pettegrew, J.W. & Keshavan, M.S. (2000) Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings - part I. Biol. Psychiatry, 48, 357-368.
53. Stanley, J.A., Williamson, P.C., Drost, D.J., Carr, T.J., Rylett, R.J., Malla, A. & Thompson, R.T. (1995) An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch. Gen. Psychiatry, 52, 399-406.
54. 31P-MR spectroscopy study. Schizophrenia Res., 13, 209-215.
55. 31P chmical-shift imaging measurements at 1.5 T. Proc. Natl Acad. Sci. USA, 88, 6810-6814.
56. Toone, B.K., Okocha, C.I., Sivakumar, K. & Syed, G.M. (2000) Changes in regional cerebral blood flow due to cognitive activation among patients with schizophrenia. Br. J. Psychiatry, 177, 222-228.
57. Veech, R.L., Lawson, J.W.R., Cornell, N.W. & Krebs, H.A. (1979) Cytosolic phosphorylation potential. J. Biol. Chem., 254, 6538-6547.
58. 31P magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics ñ A study including 50 patients and 36 controls. Biol. Psychiatry, 44, 399-404.
59. Weinberger, D.R. (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry, 44, 660-669.
60. Weinberger, D.R. (1988) Schizophrenia and the frontal lobe. Trends Neurosci., 11, 367-370.
61. Whatley, S.A., Curti, D. & Marchbanks, R.M. (1996) Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem. Res., 21, 995-1004.
62. 31P NMR chemical shifts of ATP. Anal. Biochem., 214, 458-467.
63. Williamson, P.C., Drost, D.J., Stanley, J.A., Carr, T.J., Morrison, S. & Merskey, H. (1991b) Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch. Gen. Psychiatry, 48, 578.
64. Williamson, P.C., Pelz, D., Merskey, H., Morrison, S. & Conlon, P. (1991a) Correlation of negative symptoms in schizophrenia with frontal lobe parameters on magnetic resonance imaging. Br. J. Psychiatry, 159, 130-134.
65. Yurgelun-Todd, D.A., Waternaux, C.M., Cohen, B.M., Gruber, S.A., English, C.D. & Renshaw, P.F. (1996) Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. Am. J. Psychiatry, 153, 200-205.